TCGA-05-4397-01A-01R-1206-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.550
- E2F_TARGETS+0.530
- INTERFERON_ALPHA_RESPONSE+0.510
- G2M_CHECKPOINT+0.430
- DNA_REPAIR+0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.330
- FATTY_ACID_METABOLISM+0.300
- INTERFERON_GAMMA_RESPONSE+0.290
- ADIPOGENESIS+0.270
- BILE_ACID_METABOLISM+0.240
Top 10 suppressed
- TGF_BETA_SIGNALING-0.480
- ANGIOGENESIS-0.440
- TNFA_SIGNALING_VIA_NFKB-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- UV_RESPONSE_DN-0.410
- WNT_BETA_CATENIN_SIGNALING-0.380
- KRAS_SIGNALING_UP-0.360
- HEDGEHOG_SIGNALING-0.310
- APICAL_JUNCTION-0.280
- APOPTOSIS-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-1596-01A-01R-0946-07 | — | cohortA4 | 0.887 |
| 2 | SRR12475167 | — | — | 0.863 |
| 3 | TCGA-BB-A6UM-01A-12R-A34R-07 | — | — | 0.849 |
| 4 | TCGA-66-2763-01A-01R-0851-07 | — | cohortSQ1 | 0.847 |
| 5 | MNG171 | — | — | 0.831 |
| 6 | SRR23303773 | — | — | 0.830 |
| 7 | SRR8942934 | — | — | 0.824 |
| 8 | TCGA-C8-A12U-01A-11R-A115-07 | — | B | 0.824 |
| 9 | SRR12202422 | — | — | 0.818 |
| 10 | SRR8613729 | — | E | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.550 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.210 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.170 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.170 | Remibrutinib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |